[Studies on 5-FU/PEG-PBLG nano-micelles: preparation, characteristics, and drug releasing in vivo].

Ai Zheng

Department of Medicine, Cancer Center, Sun Yat-sen University, Guangzhou, Guangdong, 510060, PR China.

Published: April 2004

Background & Objective: 5-Fluorouracil (5-FU) belongs to antimetabolic anticancer drugs and its half-life time in vivo is only about 5 minutes. Continuous infusion (48 hours,72 hours,28 days) was commonly used to maintain long-time steady-state concentration (Css). So it is necessary to exploit new slow-release system for 5-FU. This article was designed to investigate the preparation technique,shape characteristics, and drug releasing characteristics in vivo of 5-FU loaded core-shell type nanoparticles which were made by biodegradable amphiphlic poly (ethylene glycol)-poly (gamma-benzyl-L-glutamate)(PEG-PBLG).

Methods: The PEG-PBLG nano-micelles were prepared by diafiltration method. Its morphology was observed by transmission electron microscopy and scan electron microscopy. Encapsulating efficiency of 5-FU was determined by ultraviolet spectrophotometry. The 5-FU releasing characteristics from nano-micelles in vivo were investigated by high-performance liquid chromatography (HPLC).

Results: 5-FU loaded PEG-PBLG copolymer nano-micelles (5-FU/PEG-PBLG) was of round or ellipsic shape. The diameter of the micelles was 180-250 nm; the size of drug storeroom was about 200 nm and the thickness of hydrophilic zone was about 30 nm. The entrapment efficiency was (29.5+/-0.015)%. In control group, 5-FU is one-compartment in vivo; its half-life was 5.3 minutes; the maximum plasma concentration (C(max)) was 17047.3 microg/L; T(max) was the time of attaining C(max) of the end of infusion; the area under the plasma concentration-time curve (AUC) was 6263.7 microg/L x min. However, the model of nano-micelles in vivo was typical release-drug of nano-micelles namely abrupt release-slow release; its t(1/2) was 63.2 minutes; C(max) was 4563.5 microg/L; T(max) was 1.25 hours; AUC was 5794.5 microg/Lxmin. Compared with 5-FU preparation, T(max) of 5-FU/PEG-PBLG was longer (P< 0.01);C(max) was lower (P< 0.01);t(1/2) was longer (P< 0.01); AUC was similar (P >0.01).

Conclusion: The 5-FU/PEG-PBLG nano-micelles can change the pharmacokinetics of 5-FU, prolonging the circulation time in vivo and make a slow release.

Download full-text PDF

Source

Publication Analysis

Top Keywords

5-fu
9
5-fu/peg-pblg nano-micelles
8
characteristics drug
8
drug releasing
8
time vivo
8
releasing characteristics
8
5-fu loaded
8
electron microscopy
8
nano-micelles vivo
8
microg/l tmax
8

Similar Publications

The prognostic value of negative regulators of ferroptosis in patients with colorectal cancer (CRC) has not yet been fully elucidated. The present study performed a systematic identification and selection of candidate negative regulators of ferroptosis using The Cancer Genome Atlas data cohort (n=367), followed by clinical validation through immunohistochemistry of samples from patients with CRC (n=166) and further evaluation. analysis identified specific light-chain subunit of the cystine/glutamate antiporter, AIFM2, NFE2L2, FTH1, GLS2, glutathione peroxidase 4 (GPX4) and heat shock protein β-1 (HSPB1) genes as possible candidates.

View Article and Find Full Text PDF

[Chemotherapy for Metastatic Gastric Cancer].

Korean J Gastroenterol

January 2025

Department of Internal Medicine, Kosin University College of Medicine, Busan, Korea.

Gastric cancer is the fourth most common malignancy in Korea and remains the fifth and seventh leading cause of cancer death in males and females, respectively. Although the survival rates for gastric cancer have improved, unresectable or metastatic gastric cancer still has an abysmal prognosis, and the five-year survival rate for patients with stage IV gastric cancer is approximately 6.6% in Korea.

View Article and Find Full Text PDF

KGF impedes TRIM21-enhanced stabilization of keratin 10 mediating differentiation in hypopharyngeal cancer.

Cell Signal

January 2025

Key Laboratory, Department of Otolaryngology-Head and Neck Surgery, The Affiliated Hospital of Qingdao University, Qingdao University, 266003 Qingdao, China. Electronic address:

KGF, also known as FGF7, is a member of the fibroblast growth factor (FGF) family that binds with high affinity to the FGF receptor 2b (FGFR2b) and regulates various cellular processes, including cell proliferation and differentiation in a variety of tumors. However, its potential role in hypopharyngeal cancer (HPC) remains largely unknown. In our study, we observed increased expression of FGFR2b in HPC.

View Article and Find Full Text PDF

PepGAT, a chitinase-derived peptide, alters the proteomic profile of colorectal cancer cells and perturbs pathways involved in cancer survival.

Int J Biol Macromol

January 2025

Laboratory of Bioinformatics Applied to Health, Drug Research and Development Center (NPDM), Federal University of Ceará, Fortaleza, CE 60430-275, Brazil; Pharmacogenetics Laboratory, Drug Research and Development Center (NPDM), Federal University of Ceará, Fortaleza, CE 60430-275, Brazil. Electronic address:

Colorectal cancer (CRC) affects the population worldwide, occupying the first place in terms of death and incidence. Synthetic peptides (SPs) emerged as alternative molecules due to their activity and low toxicity. Proteomic analysis of PepGAT-treated HCT-116 cells revealed a decreased abundance of proteins involved in ROS metabolism and energetic metabolisms, cell cycle, DNA repair, migration, invasion, cancer aggressiveness, and proteins involved in resistance to 5-FU.

View Article and Find Full Text PDF

Importance: The effect of adjuvant chemotherapy following resection of pancreatic adenocarcinoma after preoperative (m)FOLFIRINOX (combination leucovorin calcium [folinic acid], fluorouracil, irinotecan hydrochloride, and oxaliplatin in full or modified dosing) chemotherapy on overall survival (OS) is unclear because current studies do not account for the number of cycles of preoperative chemotherapy and adjuvant chemotherapy regimen.

Objective: To investigate the association of adjuvant chemotherapy following resection of pancreatic adenocarcinoma after preoperative (m)FOLFIRINOX with OS, taking into account the number of cycles of preoperative chemotherapy and adjuvant chemotherapy regimen.

Design, Setting, And Participants: This retrospective cohort study included patients with localized pancreatic adenocarcinoma treated with 2 to 11 cycles of preoperative (m)FOLFIRINOX followed by resection across 48 centers in 20 countries from 2010 to 2018.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!